This highly diverse X-linked disorder affects over 400 million people and occurs at an average prevalence of 8% in malaria endemic nations.15 Safety concerns demand screening out patients deficient in G6PD prior to offering daily primaquine therapy, especially where clinical monitoring is impractical. Here, G6PD is linked to malaria.